Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LTG2950 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on LTG2950, putative T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, CD20, and CD22 (Sep 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LTG2950 | LTG-2950|LTG 2950 | CD19 Immune Cell Therapy 72 CD20 Immune Cell Therapy 14 CD22 Immune Cell Therapy 13 | Limited information is currently available on LTG2950, putative T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, CD20, and CD22 (Sep 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07168486 | Phase I | LTG2950 Cyclophosphamide + Fludarabine | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas | Enrolling by invitation | USA | 0 |